Literature DB >> 19559015

MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.

Yiming Li1, Weiqing Li, Yongji Yang, Yicheng Lu, Cheng He, Guohan Hu, Huimin Liu, Juxiang Chen, Jin He, Hongyu Yu.   

Abstract

MicroRNAs control a wide array of biological processes including cell differentiation, proliferation, and apoptosis whose dysregulation is a hallmark of cancer. MicroRNA-21 (miR-21) is overexpressed in many cancers including glioblastoma and contributes to tumor resistance to chemotherapy. We investigated whether miR-21 mediated chemoresistance to the chemotherapeutic agent VM-26 in glioblastoma cells and sought to identify the candidate target genes for miR-21 by gene expression profiling. Here we report that miR-21 was involved in mediating chemoresistance to VM-26 in glioblastoma cells. Suppression of miR-21 by specific antisense oligonucleotides in glioblastoma cell U373 MG led to enhanced cytotoxicities of VM-26 against U373 MG cells. We further identified and validated LRRFIP1, whose product is an inhibitor of NF-kappaB signaling, as a direct target gene of miR-21. Our findings suggest that miR-21 represents a promising target for therapeutic manipulation to increase the efficacy of chemotherapeutic agents in treating glioblastoma, a highly lethal type of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559015     DOI: 10.1016/j.brainres.2009.06.053

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  80 in total

1.  MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells.

Authors:  Yingjie Yu; Shailender S Kanwar; Bhaumik B Patel; Phil-Sun Oh; Jyoti Nautiyal; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

Review 2.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

3.  MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs.

Authors:  Arun Bhardwaj; Seema Singh; Ajay P Singh
Journal:  Mol Cell Pharmacol       Date:  2010

4.  MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.

Authors:  Johannes Voortman; Akiteru Goto; Jean Mendiboure; Jane J Sohn; Aaron J Schetter; Motonobu Saito; Ariane Dunant; Trung C Pham; Iacopo Petrini; Alan Lee; Mohammed A Khan; Pierre Hainaut; Jean-Pierre Pignon; Elisabeth Brambilla; Helmut H Popper; Martin Filipits; Curtis C Harris; Giuseppe Giaccone
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

5.  A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.

Authors:  Liqin Du; Robert Borkowski; Zhenze Zhao; Xiuye Ma; Xiaojie Yu; Xian-Jin Xie; Alexander Pertsemlidis
Journal:  RNA Biol       Date:  2013-09-30       Impact factor: 4.652

Review 6.  NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

Authors:  G Kenneth Gray; Braden C McFarland; Susan E Nozell; Etty N Benveniste
Journal:  Expert Rev Neurother       Date:  2014-09-29       Impact factor: 4.618

7.  Noncoding RNAs and LRRFIP1 regulate TNF expression.

Authors:  Lihua Shi; Li Song; Michael Fitzgerald; Kelly Maurer; Asen Bagashev; Kathleen E Sullivan
Journal:  J Immunol       Date:  2014-02-24       Impact factor: 5.422

8.  Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4.

Authors:  Young Mi Park; Su Jin Hwang; Kiyoshi Masuda; Kyung-Min Choi; Mi-Ran Jeong; Do-Hyun Nam; Myriam Gorospe; Hyeon Ho Kim
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

9.  Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Authors:  Jin-Hyeok Hwang; Johannes Voortman; Elisa Giovannetti; Seth M Steinberg; Leticia G Leon; Yong-Tae Kim; Niccola Funel; Joo Kyung Park; Min A Kim; Gyeong Hoon Kang; Sun-Whe Kim; Marco Del Chiaro; Godefridus J Peters; Giuseppe Giaccone
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

10.  MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.

Authors:  Y Tomimaru; H Eguchi; H Nagano; H Wada; A Tomokuni; S Kobayashi; S Marubashi; Y Takeda; M Tanemura; K Umeshita; Y Doki; M Mori
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.